

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors.  
Follow this format for each person. DO NOT EXCEED FIVE PAGES.

NAME: Stephanie J. Lee

eRA COMMONS USER NAME (credential, e.g., agency login): Stephanie\_Lee

POSITION TITLE: Professor of Medicine

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
University of Washington, Seattle, WA	B.S.	06/1984	Microbiology/Immunology
Stanford University School of Medicine, CA	M.D.	06/1990	Medicine
Harvard School of Public Health, Boston, MA	M.P.H.	06/1996	Clinical Effectiveness

**A. Personal Statement**

My scholarly work has focused on outcomes after hematopoietic cell transplantation, with particular attention to studies of chronic graft-versus-host disease and other late complications. I am the Principal Investigator of the "Chronic GVHD Consortium," a network of transplant centers who work together to conduct observational and therapeutic studies in chronic GVHD. The Consortium conducts prospective observational studies as well as clinical trials: all studies include patient-reported outcomes, clinician-reported information, corollary biologic studies and biorepositories. I also hold a number of other leadership roles including Research Director of the Fred Hutchinson Long-Term Follow-Up (LTFU) Program for the transplant program that follows more than 6,500 survivors, Co-Scientific Director of the Immunobiology Working Committee and the Graft-vs.-Host Disease Working Committee for the Center for Blood and Marrow Transplantation Research (CIBMTR), Vice Chair of the Blood and Marrow Transplant Clinical Trials Network, and Section Head, Hematologic Malignancies, Clinical Research Division at Fred Hutchinson Cancer Center. I was the 2020 President of the American Society of Hematology (ASH) the largest professional organization of hematologists with over 18,000 members. I am an attending transplant physician with the Blood and Marrow Transplant group at the Fred Hutchinson Cancer Center.

Ongoing projects that I would like to highlight include:

R01 CA118953

Lee, SJ

07/18/07 – 03/31/26

Improving Outcomes Assessment in Chronic Graft vs. Host Disease

U01 CA236229

Lee, SJ

07/02/19 - 06/30/24

Biologic Correlatives of Chronic GVHD Onset

R01 FD006836

Lee, SJ, Pidala, J

08/24/20 - 07/31/25

Ustekinumab for graft versus host disease prevention (IND 144540)

## Citations:

1. **Lee SJ**, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, Pidala J, Olivieri A, Martin P, Przepiorka D, Pusic I, Dignan F, Mitchell S, Lawitschka A, Jacobsohn D, Hall AM, Vogelsang B, Pavletic S. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. *Biol Blood Marrow Transplant* 2015; 21: 984-999. PMID: PMC4744804.
2. Jagasia M, Lazaryan A, Bachier CR, Salhotra A, Weisdorf DJ, Zoghi B, Essell J, Green L, Schueller O, Patel J, Zanin-Zhorov A, Weiss JM, Yang Z, Eiznhamer D, Aggarwal SK, Blazar BR, **Lee SJ**. ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease. *J Clin Oncol* 2021; 39: 1888-1898 PMID: 33877856. PMID: PMC8189612
3. Wolff D, Radojicic V, Lafyatis R, Cinar R, Rosenstein RK, Cowen EW, Cheng GS, Sheshadri A, Bergeron A, Williams KM, Todd JL, Teshima T, Cuvelier GDE, Holler E, McCurdy SR, Jenq RR, Hanash AM, Jacobsohn D, Santomasso BD, Jain S, Ogawa Y, Steven P, Luo ZK, Dietrich-Ntoukas T, Saban D, Bilic E, Penack O, Griffith LM, Cowden M, Martin PJ, Greinix HT, Sarantopoulos S, Socie G, Blazar BR, Pidala J, Kitko CL, Couriel DR, Cutler C, Schultz KR, Pavletic SZ, **Lee SJ\***, Paczesny S\*. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-host disease: IV. The 2020 Highly Morbid Forms Report. *Transplant Cell Ther* 2021; 27: 817-835 \*co-senior authors PMID: 34217703. PMID: PMC8478861
4. Kitko CL, Arora M, DeFilipp Z, Abu Zaid M, Di Stasi A, Radojicic V, Betts CB, Coussens LM, Meyers ML, Qamoos H, Ordentlich P, Kumar V, Quaranto C, Schmitt A, Gu Y, Blazar BR, Wang TP, Salhotra A, Pusic I, Jagasia M, **Lee SJ**. Axatilimab for chronic graft-versus-host disease after failure of at least 2 prior systemic therapies: results of a phase 1/2 study. *J Clin Oncol* 2023, in press. PMID: 36459673

## B. Positions, Scientific Appointments, and Honors

### Positions and Scientific Appointments:

2011-2006-2011	Professor, Fred Hutchinson Cancer Center and Professor, University of Washington, Seattle, WA
1999-2005	Associate Member, Fred Hutchinson Cancer Research Center and Associate Professor, University of Washington, Seattle, WA
1999-2005	Assistant Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
1990-1993	Intern and Resident in Internal Medicine, Stanford Medical Center, Stanford, CA
1996-1999	Instructor in Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
1993-1996	Clinical and Research Fellow in Medicine (Hematology/Oncology), Brigham and Women's Hospital, Harvard Medical School, Boston, MA

### Honors:

2023-2022	Vice Chair, Chair-Elect, Chair, Past-Chair Blood and Marrow Transplant Clinical Trials Network
2022	American Society of Hematology Exemplary Service Award
2019-	Association of American Physicians
2018-	David and Patricia Giuliani/Oliver Press Endowed Chair in Cancer Research
2018-2020	Vice President, President Elect, President, Executive Committee, American Society of Hematology
2013-2016	Secretary, Executive Committee, American Society of Hematology
2011-	Editorial Board, Bone Marrow Transplantation
2009-	American Society of Clinical Investigation
2009-2011	Treasurer, Executive Committee, American Society of Blood and Marrow Transplantation
2009-2014	Editorial Board, Journal of Clinical Oncology
2008-2011	Executive Committee, American Society of Hematology
2005-2008	Board of Directors, American Society of Blood and Marrow Transplantation
2003-	Editorial Board, Biology of Blood and Marrow Transplantation, now Transplant and Cellular Therapy

### C. Addition Contributions to Science beyond Chronic GVHD

**Quality of life, tools and interventions.** I developed a patient-reported outcomes (PRO) tool for chronic graft-versus-host disease that is now the recommended PRO tool in this area. I am interested not only in improving QOL through better measurement and interventions but also in understanding how information about QOL is incorporated into medical decision making and patient management.

- a) **Lee SJ**, Cook EF, Soiffer RJ, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. *Biol Blood Marrow Transplant* 2002; 8: 444-452. PMID: 12234170.
- b) **Lee SJ**, Logan B, Westervelt P, Cutler C, Woolfrey A, Khan SP, Waller EK, Maziarz RT, Wu J, Shaw BE, Confer D, Horowitz MM, Anasetti C. Comparison of patient-reported outcomes in 5 year survivors who received bone marrow vs. peripheral blood unrelated donor transplantation. *JAMA Onc* 2016, 2: 1583-1589. PMID: PMC5145732.
- c) **Lee SJ**, Onstad L, Chow EJ, Shaw BE, Jim HSL, Syrjala KL, Baker KS, Buckley S, Flowers ME. Patient-reported outcomes and health status associated with chronic GVHD. *Haematologica* 2018, 103: 1535-1541. PMID 29858386
- d) Buckley SA, Halpern AB, Othus M, Jimenez-Sahagun DJ, Walter RB, **Lee SJ**. Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemia. *LeukLymph*, 2020; 61: 1158-1167. PMID: 31909637

**Late effects after hematopoietic cell transplantation.** As research director of the LTFU since 2013, I have been involved in many studies of late effects and survivorship. This work tries to educate clinicians and survivors about surveillance and treatment approaches that can mitigate late effects.

- a) Khera N, Chow EJ, Leisenring WM, Syrjala KL, Baker KS, Flowers MED, Martin PJ, **Lee SJ**. Factors associated with adherence to preventive care practices among hematopoietic cell transplantation survivors. *Biol Blood Marrow Transplant* 2011; 17: 995-1003. PMID: PMC3062948.
- b) Chow EJ, Mueller BA, Baker KS, Cushing-Haugen KL, Flowers MED, Martin PJ, Friedman DL, **Lee SJ**. Cardiovascular hospitalizations and mortality among recipients of hematopoietic cell transplantation. *Ann Intern Med* 2011; 155: 21-32. PMID: 21727290.
- c) Khera N, Storer B, Flowers ME, Carpenter PA, Inamoto Y, Sandmaier BM, Martin PJ, **Lee SJ**. Nonmalignant late effects and compromised functional status in hematopoietic cell transplantation. *J Clin Oncol* 2012; 30: 71-77. PMID: PMC3255560.
- d) Rosenberg AR, Syrjala KL, Martin PJ, Flowers ME, Carpenter P, Salit RB, Baker S, **Lee SJ**. Resilience, health, and quality of life among long-term survivors of hematopoietic cell transplant. *Cancer* 2015; 23: 4250-4257. PMID: PMC4666727.

**Outcomes research in hematopoietic cell transplantation.** I have led many observational studies that describe prognostic factors and treatment outcomes. I am particularly interested in how this information is used to improve treatment choices.

- a) **Lee SJ**, Fairclough D, Antin JH, Weeks JC. Discrepancies between patient and physician estimates for the success of stem cell transplantation. *JAMA*. 2001; 285:1034-8. PMID: 11209174.
- b) Kirtane K, **Lee SJ**. Racial and ethnic disparities in hematologic malignancies. *Blood* 2017; 130: 1699-1705. PMID: 28724539.
- c) Shaw BE, Syrjala KL, Onstad L, Chow EJ, Flowers ME, Jim H, Baker KS, Buckley S, Fairclough D, Jensen RE, Horowitz MM, **Lee SJ**. PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. *Cancer* 2018; 124: 841-849. PMID 29072787.
- d) **Lee SJ**, Nguyen TD, Onstad L, Bar M, Krakow EF, Salit RB, Carpenter PA, Rodrigues M, Hall AM, Storer BE, Martin PJ, Flowers ME. Success of immunosuppressive treatments in patients with chronic graft-versus-host disease. *Biol Blood Marrow Transplant* 2018; 24: 555-562. PMID: 29133250.

**Immunobiology.** As the Co-Scientific Director of the Immunobiology committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), I participate in all of the CIBMTR studies in this area which try to define the genetic determinants of transplant success.

- a) **Lee SJ**, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley CK, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams TM, Anasetti C. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. *Blood* 2007; 110: 4576-4583. PMID: 17785583.

- b) Woolfrey A, Klein JP, Haagenson M, Spellman S, Petersdorf E, Oudshoorn M, Gajewski J, Hale GA, Horan J, Battiwalla M, Marino SR, Setterholm M, Ringden O, Hurley C, Flomenberg N, Anasetti C, Fernandez-Vina M, **Lee SJ**. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. *Biol Blood Marrow Transplant* 2010; 17: 885-892. PMID: PMC3071866.
- c) Pidala J, **Lee SJ**, Ahn KW, Spellman S, Wang HL, Aljurf M, Askar M, Dehn J, Fernandez-Vina M, Gratwohl A, Gupta V, Hanna R, Horowitz MM, Hurley CK, Inamoto Y, Kassim AA, Nishihori T, Mueller C, Oudshoorn M, Petersdorf EW, Prasad V, Robinson J, Saber W, Schultz KR, Shaw B, Storek J, Wood WA, Woolfrey AE, Anasetti C. Nonpermissive HLA-DPB1 mismatch increases mortality after unrelated allogeneic hematopoietic cell transplantation. *Blood* 2014; 124: 2596-2606. PMID: PMC4199961.
- d) Gadalla SM, Aubert G, Wang T, Haagenson M, Spellman SR, Wang L, Katki HA, Savage SA, **Lee SJ**. Donor telomere length and causes of death after unrelated hematopoietic cell transplant in patients with marrow failure. *Blood* 2018; 131: 2393-2398. PMID 29632022.

**Complete List of Published Work in MyBibliography:**

<https://www.ncbi.nlm.nih.gov/sites/myncbi/stephanie.lee.1/bibliography/45219487/public/?sort=date&direction=descending>